Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$150,000.00

Amyloid-Based Therapies for Type 2 Diabetes

EF 2008-09

Résumé
Amyloidoses involve the abnormal deposition of protein fibrils or plaques within tissues leading to extensive cellular damage. Amyloid plaques are associated with a number of disorders including Alzheimer's disease and type-2 diabetes which are the focus of our research program. Although each is unique, all amyloid proteins can under certain conditions assemble in to morphologically and structurally identical fibrillar or thread-like structures. This suggests that amyoid deposits are formed by similar mis-folding pathways and therefore therapeutic interventions to control these events may be beneficial for these diseases. We propose to address this problem with a comprehensive strategy that will combine biophysical and biochemical approaches to the development of amyloid inhibiting drugs for the treatment of diabetes. This will be accomplished in conjunction with the development of cellular novel models that recreate the pathological features associated with type-2 diabetes and provide test vehicles for the evaluation of these drugs. Our ultimate goals are to understand the causes of diabetes and to develop a means to prevent or delay the progression of the disease.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
174440
Name
Fraser Paul E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Amyloid-Based Therapies for Type 2 Diabetes
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Beta Cells; Diabetes; Islet Amyloid; Peptide Chemistry; Pharmacokinetics
Abstract
Amyloidoses involve the abnormal deposition of protein fibrils or plaques within tissues leading to extensive cellular damage. Amyloid plaques are associated with a number of disorders including Alzheimer's disease and type-2 diabetes which are the focus of our research program. Although each is unique, all amyloid proteins can under certain conditions assemble in to morphologically and structurally identical fibrillar or thread-like structures. This suggests that amyoid deposits are formed by similar mis-folding pathways and therefore therapeutic interventions to control these events may be beneficial for these diseases. We propose to address this problem with a comprehensive strategy that will combine biophysical and biochemical approaches to the development of amyloid inhibiting drugs for the treatment of diabetes. This will be accomplished in conjunction with the development of cellular novel models that recreate the pathological features associated with type-2 diabetes and provide test vehicles for the evaluation of these drugs. Our ultimate goals are to understand the causes of diabetes and to develop a means to prevent or delay the progression of the disease.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fraser, Paul E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~